International guidelines for the treatment of human immunodeficiency virus (HIV) infection change rapidly. They are mainly based on results from large-scale randomized clinical trials, but also on hypotheses. The objective of the study was to look at the use of antiretrovirals (ARVs) in different HIV treatment centres in Europe. Between August 1996 and September 1997 selfadministered anonymous questionnaires were distributed to persons with HIV infection at inpatient and outpatient departments in 11 European countries; 1,366 people completed the questionnaire. Important differences in use of ARVs were noted between different centres. Zidovudine was the drug that was used predominantly in all countries and by 77% of all patients; the use of didanosine, zalcitabine and stavudine differed widely. Use of ARVs was found to be lower for people who reported intravenous drug use (compared to homosexual transmission), people with a low education level, and those with a monthly income lower than 992 Euro. The use of a protease inhibitor containing ARV treatment regimen was significantly lower in the centres in the south of Europe. Between 1996 and 1997, many persons with HIV infection in Europe received a suboptimal ARV treatment regimen. Use of ARVs should be improved for intravenous drug users, persons with lower educational level and lower income.
Introduction
Treatment strategies for Human Immunodeficiency Virus (HIV) infection change rapidly and international guidelines are being updated continuously (BHIVA, 2000; Carpenter et al., 2000; Department of Health and Human Services, 2000) . The organization of health care, regulations and budgets vary between countries, and physicians may not follow international or even national guidelines. The availability of drugs may govern the decision whether to prescribe a given regimen. Finally, patients may decide not to take the antiretrovirals (ARVs) as prescribed by their physician.
In 1995, a European project (Eurosupport) was launched to assess the quality of support for people with the HIV infection. Eurosupport is a European project sponsored by the European Commission and co-ordinated by the Institute of Tropical Medicine, Antwerp, Belgium. Between 1996 and 1997 , Eurosupport organized a survey in 11 participating countries, using an anonymous questionnaire, mainly to determine care and support needs for people with HIV infection. In this paper we review how people with HIV infection in Europe at that time were treated with antiretrovirals (ARVs): which drugs were given at the time of the study and which factors might influence use of ARV therapy, and more specifically protease inhibitors.
Methods

Questionnaire
Questionnaires were translated into the official languages of the participating countries and adapted to the local situations (e.g. currencies). Translated questionnaires were reviewed by the co-ordinating centre to check for uniformity. The questionnaires were pretested by a group of patients in different countries to check for clarity of the questions. These test questionnaires were excluded from analysis. The questionnaires were distributed by HIV/ AIDS treatment centres and non-governmental organizations (NGOs) from August 1996 to September 1997 (see Acknowledgements). For practical reasons we will refer to countries rather than specific centres in this paper. The participating centres are not necessarily representative for each country.
Questionnaires were handed out to consecutive patients with HIV infection, seen at HIV treatment centres and completed anonymously. Persons diagnosed with HIV infection for less than one year or who did not understand one of the main languages of the participating country or were unable to complete the questionnaire without assistance were excluded. The questionnaire included questions on the use of ARVs, participation in clinical trials, perceived stage of illness, perceived way of HIV transmission, psychosocial support and other HIV care issues. The data collection period varied from five months in Belgium, France, Italy, Luxembourg and Spain to 13 months in Germany, Portugal and the UK ( Table 1) .
The participating countries were divided into two regions: North-Central Europe (consisting of Denmark, UK, The Netherlands, Belgium, Luxembourg, Germany and France) and Southern Europe (with Portugal, Spain, Italy and Greece).
The mode of infection was divided into heterosexual, homosexual, intravenous drug use (IVDU), and others. People who reported both homosexual activities and IVDU (n 5 5; 0.41%), and bisexual males (n 5 7; 0.51%) were included as homosexuals.
Statistics
Baseline parameters considered as potential predictors of ARV therapy were: age, sex, CD4 cell count, education, income, HIV transmission category and stage of HIV disease and region. Bivariate analysis was done to explore these potential covariates. To check for possible confounding, these factors were entered into a multivariate logistic regression model using a backward procedure (entry level 0.05, removal level 0.10). Analyses were performed using SPSS, version 7.5. (1) to outpatients by staff of an HIV/AIDS treatment centre;
(2) by self-support group volunteers (during workshops, and/or at hospitals to in/outpatients).
Results
Study population
A total of 1,366 people completed the questionnaire (50% of distributed questionnaires).
Most of the study participants were male (81%). The mean age of the study population was 38 years (SD 5 9 years, range 5 18-75). More than half of the respondents reported HIV transmission through male homosexual contact (varying from 23% in Spain, to 81% in the UK). See Table 2 . The mean known duration of HIV status was six years. Forty-four per cent of the patients considered themselves to be without symptoms, 33% to be symptomatic without AIDS and 19% considered themselves to have AIDS. About 40% of the participants reported having a CD4 lymphocyte count of less than 200/mm 3 (85% of the CD4 lymphocyte counts were obtained in the previous three months). Four hundred and forty-eight respondents (34%) were not taking ARV treatment at the time of the study. Two hundred and eighty-nine (64.5% of the people who were not taking ARV treatment) had a CD4 count of less than 500/mm 3 .
ARV treatment regimens used
At the time of the study, 382 (27%) of the participants were taking a protease inhibitor (PI) containing triple therapy combination: PIs were often taken in the Netherlands and Germany (51 and 44%, respectively), and less frequently in Portugal and Spain (13 and 19%, respectively) . Indinavir was the most frequently prescribed PI (196 participants (14%)). Saquinavir plus two NRTIs were used by 110 (8%) respondents at the time of the study Table 2 . (varying from 0% in Denmark and the Netherlands to 18% in Italy). See Figure 1 and Table 3 . The top three regimens were zidovudine plus lamivudine (106 (8%) participants), indinavir plus lamivudine plus zidovudine (93 (7%) participants) and indinavir plus stavudine 1 lamivudine (77 (6%) participants).
Demographics of the study participants
A few participants (4%) were still being treated with monotherapy (range 5 0% in Luxembourg to 8% in Belgium). Very few patients received non-nucleoside reverse transcriptase inhibitors (NNRTI) or quadruple therapy.
Predictors for receiving ARV therapy
The multivariate analysis showed that CD4 cell count, income, education, HIV transmission category and region were significant predictors for receiving ARV therapy (Table 4) . People with a monthly income higher than 992 (OR 5 1.35; 95% CI: 1.01-1.81), with higher education (OR 5 1.78; 95% CI: 1.24-2.54) or from the south of Europe (OR 5 1.62; CI: 1.16-2.25) were more likely to receive ARV treatment. People infected via IVDU were receiving ARV treatment significantly less often than were homosexuals (OR 5 0.57; CI: 0.36-0.90). The multivariate analysis showed only CD4 cell count, region and stage of HIV disease to be significant predictors for receiving a PI-containing treatment regimen (Table 5) . People from the Southern region were less likely to receive a PI compared to people in Northern and Central Europe (OR 5 0.56; 95% CI: 0.41-0.77). People with a CD4 cell count higher than 200/mm 3 or people with no HIV-related diseases were less likely to receive a PI-containing regimen.
Discussion
In the period August 1996 to September 1997, important differences were noted in the use of ARVs among persons with HIV infection from different centres in Europe. Differences in Table 3 .
Treatment regimens at the time of the study (%)
Countries and regions the use of ARVs in Europe have also been described previously (Carrieri et al., 1999; Chiesi et al., 1999) . In the 'AIDS in Europe' study conducted in 1989, AIDS patients from Southern Europe received ARVs less frequently than patients from Central and Northern Europe (Carrieri et al., 1999) . On the other hand, in a study of 3,122 European HIV-infected patients (EuroSIDA Study, 1994) , ARVs were more frequently used among patients from Southern and Central Europe compared with patients from Northern Europe, especially among patients with CD4 lymphocyte counts above 200 cells/:l (73, 57 and 42%, respectively). Based on the latter study, it was suggested that the earlier access and the greater proportions of persons with HIV infection treated with PIs, could explain the lower HIV mortality rates observed in Central Europe . In our survey, a significant percentage of persons reported receiving suboptimal ARV treatment: 4% were receiving monotherapy; of those treated with triple combination therapy, a relatively large percentage were treated with saquinavir (hardgel) as the only PI. None of the patients from Denmark and the Netherlands reported the use of saquinavir, in contrast with Italy, where 18% of the patients reported the use of saquinavir. Because of the low bio-availability of this drug this may have favoured the development of resistance, not only against saquinavir, but also against other PIs.
This survey demonstrated that people with lower income, lower education and IV drug users were less likely to use ARVs. However, we do not know to what degree this was because of lack of interest in ARVs or because of lack of access to ARVs. People from Southern Europe were more likely to have received ARVs but less likely to have received a PI-containing regimen. Some differences in the use of ARVs could be explained by different ways these drugs are approved by regulatory authorities, drug prices, reimbursement, etc. Although many countries have made progress, patients in certain European countries still have to wait much longer before new ARVs become available compared to the USA. In Belgium (e.g. in May 2000) it is very difficult to obtain efavirenz (because of a dispute between the company and the government about the price of this drug) and the 200mg formulation of didanosine as well as the capsulated formulation of nelfinavir are not available at all. Several studies have demonstrated that suboptimal treatment regimens are associated with development of resistance, increased morbidity and mortality Lucas et al., 1999) . An increasing number of patients are failing first-and second-line regimens, causing a great need for new ARVs (Deeks et al., 1999; Piketty et al., 1999) . Making these new drugs available more quickly for patients will not increase treatment costs but reduce them because they will replace ineffective antivirals.
We believe that in Europe today, there are still large differences in the way people with HIV infection are treated and in the way the monitoring of this treatment is organized (using viral load, resistance and drug level measurements). In order to optimize therapy for everybody, there should be sufficient access to new ARVs and laboratory tests for treatment monitoring. Physicians have to follow international guidelines (which should be updated regularly) and patients should be supported to adhere to their ARV treatment regimens.
In this study no correlation between receiving ARVs and gender was observed. IVD users on the other hand, were less likely than homosexual men to have received ARV treatment. Others have reported a similar finding (Carrier et al., 1999; Lundgren et al., 1997) .
The results of this study should be interpreted with caution. Participating centres were contacted through an existing network of HIV professionals. One or two centres per country participated. These centres are not necessarily representative for their country.
If we consider, however, the demographic characteristics of the people participating in the study (sex, age, mode of HIV transmission), these characteristics were quite comparable with those of people with HIV infection in the different countries. The method and time period of distribution varied from centre to centre (Table 1) . Centres who distributed the questionnaires earlier might have had less opportunity to obtain the newest drugs. There were important differences in response rates between centres. This could have been related to the different demographics of the people with HIV infection seen in these centres, but also by the way potential participants were motivated by clinic staff to return completed questionnaires. Information about non-respondents was not available. Finally, treatment regimens may not always have been reported correctly by patients.
Differences between EuroSIDA and Eurosupport findings are probably related to differences in methodology, inclusion criteria and participating centres. Both the EuroSIDA cohort and the Eurosupport survey have problems with representability of their study participants. Therefore both studies should be considered as complementary. Neither of the studies included people with HIV infection who did not receive care or people unaware of their HIV status. As antiretroviral treatment regimens become more effective, we hope that an increasing number of individuals with risky behaviour will be willing to undergo an HIV test and when tested positive, will consider starting highly active antiretroviral treatment if indicated.
There are now more than 15 ARVs available for use in Europe. It is likely that in the future, HIV treatment centres across Europe will continue to choose different ARV treatment regimens, because it is so far unclear which treatment regimens are optimal. Treatment regimens initially thought to be the most effective ones, such as the PI-containing regimens, may suddenly become less popular due to the recognition of long-term side effects (Wanke, 1999) . Clinical trials can answer specific questions within a well-defined study design, but do not give information about the actual treatment situation in the general population. This can only be done by following patients in large cohorts and by organizing large surveys among patients.
